2022年，国际脑淀粉样血管病协会发布了《脑淀粉样血管病的波士顿标准2.0》。该诊断标准在前一版本的基础上进行了多项重要更新，包括下调了脑淀粉样血管病的诊断年龄标准，新增了大脑凸面蛛网膜下腔出血、短暂局灶性神经症状发作、认知障碍和（或）痴呆等临床表现，并引入了多项出血性和非出血性影像学标志物。与既往诊断标准相比，最新版标准的诊断敏感度显著提升，尤其在有症状性脑出血的患者中表现出优越的诊断效能。本文结合本团队的临床实践经验以及中国患者的脑库病理学调查结果，对《脑淀粉样血管病的波士顿标准2.0》的核心内容进行解读，以供国内同道参考。

In 2022, the International Cerebral Amyloid Angiopathy Association published the Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRIneuropathology diagnostic accuracy study. This updated version has made significant revisions, including lowering the minimum age for diagnosing cerebral amyloid angiopathy, adding symptoms such as convexal subarachnoid hemorrhage, transient focal neurological episodes, and cognitive impairment/dementia, and incorporating multiple hemorrhagic and non-hemorrhagic imaging biomarkers. Compared with previous diagnostic versions, this latest version of the criteria demonstrates significantly improved diagnostic sensitivity, particularly in patients with symptomatic intracerebral hemorrhage. Therefore, this paper aims to summarize the Boston criteria version 2.0 for cerebral amyloid angiopathy with evidence from China Brain Bank and the clinical practice experience of our team as references for domestic peers.